AI in Healthcare
The latest on artificial intelligence transforming medicine
News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.
Biologic Drug Discovery Is Entering an AI-Driven Design Era
AI is increasingly shaping biologic drug discovery, where protein engineering and antibody design depend on combinatorial complexity that humans cannot efficiently search alone. The likely winners will be teams that combine model-driven design with experimental feedback, not those that treat AI as a substitute for lab science.
Small Meets Large: Pharma Rethinks the Molecule Divide in a More AI-Native R&D Model
A new industry analysis argues that the historic split between small molecules and large molecules is becoming less useful in pharmaceutical R&D. As AI-driven design and platform biology mature, developers are increasingly organizing around disease mechanisms, developability, and modality fit rather than legacy chemistry silos.
Earendil’s $787 Million Raise Signals Investor Appetite for AI Biologics at Scale
Earendil has raised $787 million to expand an AI-led biologics strategy, one of the largest recent financings in computational biotech. The round underscores that investors still back platform stories when they target large, high-value therapeutic categories and present a path from model development to drug creation.
Earendil Labs’ $787 Million Raise Shows Investor Appetite for AI-Enabled Biologics Is Still Strong
Earendil Labs has reportedly secured $787 million to support a biologics development push. In a tougher market for AI drug discovery, that scale of financing suggests investors still have conviction when a company’s strategy aligns advanced computation with high-value therapeutic modalities.
AI-Designed T-Cell Engager Heads to AACR, Offering a Concrete Test of Generative Oncology Claims
The presentation of AI-designed T-cell engager LGTX-101 at AACR gives the field something it has often lacked: a tangible therapeutic candidate tied to a major scientific meeting. Its importance lies in whether the data can show that AI is contributing not just speed, but a differentiated molecular design strategy in immuno-oncology.
Nature Highlights AI’s Growing Role in Finding Better Antibody Binders
A new Nature report describes AI methods that speed the search for antibody binders with more drug-like properties. The work matters because it points beyond simple binding prediction toward models that optimize for the manufacturability and developability constraints that often derail biologics programs.
How this works
Discover
An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.
Structure
The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.
Publish
Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.